ADMA Biologics Inc (ADMA)

Receivables turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	426,454	382,809	330,245	283,177	258,216	234,293	208,108	181,890	154,079	130,481	110,072	93,998	80,944	68,517	58,112	48,069	42,220	40,301	37,248	36,021
Receivables	US$ in thousands	49,999	50,140	30,113	49,600	27,421	31,319	36,732	26,518	15,505	20,902	18,884	25,630	28,577	20,393	23,545	15,362	13,237	6,335	6,514	7,108
Receivables turnover		8.53	7.63	10.97	5.71	9.42	7.48	5.67	6.86	9.94	6.24	5.83	3.67	2.83	3.36	2.47	3.13	3.19	6.36	5.72	5.07

December 31, 2024 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $426,454K ÷ $49,999K
= 8.53

The receivables turnover ratio for ADMA Biologics Inc has shown fluctuations over the defined periods. The ratio indicates how many times a company collects its average accounts receivable balance during a specific period.

Looking at the data provided, we observe that the receivables turnover ratio ranged from a low of 2.47 (June 30, 2021) to a high of 10.97 (June 30, 2024) over the given quarters. The company's ability to collect its outstanding receivables improved significantly between June 30, 2021, and June 30, 2024, prior to declining slightly by December 31, 2024.

The trend of the receivables turnover ratio suggests that ADMA Biologics Inc has generally been efficient in collecting its accounts receivable. High turnover ratios typically indicate that the company is collecting payments from its customers quickly, which is a positive sign for its liquidity and cash flow management.

It is advisable for stakeholders to monitor the receivables turnover ratio consistently, as sudden drops or fluctuations could indicate potential issues with collecting payments from customers or changes in the company's credit policy.